Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis

被引:5
作者
Tejada, Romina A. [1 ]
Malagon, Talia [1 ]
Franco, Eduardo L. [1 ]
机构
[1] McGill Univ, Gerald Bronfman Dept Oncol, Div Canc Epidemiol, 5100 Maisonneuve Blvd West,Suite 720, Montreal, PQ H4A 3T2, Canada
基金
加拿大健康研究院;
关键词
Papillomavirus Vaccines; Cervical cancer; Cost-Benefit Analysis; Latin America; CERVICAL-CANCER; HPV VACCINATION; QUADRIVALENT VACCINE; ECONOMIC-EVALUATION; HEALTH; IMPACT; WOMEN; THRESHOLDS; PREVENTION; INFECTION;
D O I
10.1016/j.vaccine.2022.03.046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Cervical cancer is a major public health problem in Latin America. Cost-effectiveness studies help stakeholders with decisions regarding human papillomavirus (HPV) vaccination programs, one of the main prevention measures. Our objective was to synthesize the results of cost-effectiveness studies of HPV vaccination in girls, to understand factors influencing cost-effectiveness in the region. Methods: We systematically searched databases as well as repositories from conferences, Ministries of Health and Health Technology Assessment offices. Incremental cost-effectiveness ratios (ICERs) were extracted, with data converted to international dollars (I$) and inflated to 2019 values. We used the gross domestic product per capita as threshold for judging the cost-effectiveness of vaccination. We calculated the geometric mean ICER by type of vaccine, whether screening (cytology or HPV test) was used as com-parator, effectiveness measure, perspective, source of funding, year of cost, and country. Results: We found 24 studies. Despite the methodological differences, most studies concluded that HPV vaccination of girls in Latin American countries was either cost-saving or cost-effective. The mean ICER was I$ 3,804 for the bivalent vaccine, I$ 640 for the quadrivalent and I$ 358 for a generic HPV-16/18 vac-cine. The mean ICER was lower in the studies that used HPV DNA test instead of cytology (I$ 122 vs I$ 1,841) as comparator; used the societal perspective (I$ 235 vs. I$ 1,986); were funded by non-profit sources instead of by pharmaceutical industry (I$ 421 vs. I$ 2,676); and used costs obtained prior to 2008 (I$ 365 vs I$ 1,415). We observed great variation in the mean ICERs by effectiveness measure (I$ 402 for per disability adjusted life years, I$ 461 for life year saved, and I$ 1,795 for quality adjusted life years). Conclusions: Most studies concluded that HPV vaccination of girls in Latin America countries was cost-saving or cost-effective, despite heterogeneity between models. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2667 / 2678
页数:12
相关论文
共 70 条
[51]   THE EFFICIENCY PATH: AN ESTIMATION OF COST-EFFECTIVENESS THRESHOLDS FOR 185 COUNTRIES BASED ON PER CAPITA HEALTH EXPENDITURES AND LIFE EXPECTANCY [J].
Pichon-Riviere, A. ;
Augustovski, F. ;
Garcia Marti, S. ;
Caporale, J. .
VALUE IN HEALTH, 2015, 18 (07) :A695-A695
[52]  
Pichon-Riviere A, 2015, SALUD PUBLICA MEXICO, V57, P504
[53]  
Porta M., 2008, DICCIONARY EPIDEMIOL
[54]   Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico [J].
Reynales-Shigematsu, Luz Myriam ;
Rodrigues, Eliane R. ;
Lazcano-Ponce, Eduardo .
ARCHIVES OF MEDICAL RESEARCH, 2009, 40 (06) :503-513
[55]  
Secretaria de Cincia Tecnologia e Insumos Estratgicos Departamento de Cincia e Tecnologia Ministerio de Salud, 2009, DIR MET EST AV EC TE, P145
[56]   The Cost Effectiveness of Human Papillomavirus Vaccines A Systematic Review [J].
Seto, Katherine ;
Marra, Fawziah ;
Raymakers, Adam ;
Marra, Carlo A. .
DRUGS, 2012, 72 (05) :715-743
[57]   Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination [J].
Siok Shen Ng ;
Hutubessy, Raymond ;
Chaiyakunapruk, Nathorn .
VACCINE, 2018, 36 (19) :2529-2544
[58]   Cost-effectiveness of vaccination against cervical cancer:: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios [J].
Suarez, Eugenio ;
Smith, Jennifer S. ;
Bosch, F. Xavier ;
Nieminen, Pekka ;
Chen, Chien-Jen ;
Torvinen, Saku ;
Demarteau, Nadia ;
Standaert, Baudouin .
VACCINE, 2008, 26 :F29-F45
[59]  
Tatkan G, 2018, W INDIAN MED J, V67, P33
[60]   Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review [J].
Techakehakij, Win ;
Feldman, Roger D. .
VACCINE, 2008, 26 (49) :6258-6265